Cord Blood America Secures $7.5 Million Investment

July 7, 2009 (FinancialWire) — Cord Blood America, Inc. (OTCBB: CBAI) (Current Market Cap: $5.53 Mil.), a firm that preserves umbilical cord blood stem cells, said it has entered into a definitive agreement with a health care fund under which the company has secured a $7.5 million investment capital commitment.

The investment may drawdown funds from the fund, based on terms and market conditions, through the issuance of series A preferred stock and five-year warrants exercisable for shares of common stock.

Cord Blood plans to use the proceeds to fund new stem cell initiatives, potential acquisitions, and working capital needs.

company founder and CEO Matthew Schissler said the proceeds, once available and when coupled with internally generated revenues, should be sufficient to fund operations in the foreseeable future.

Santa Monica, California-based Cord Blood America facilitates umbilical cord blood stem cell preservation for expectant parents and their children. According to the firm, cord blood stem cells offer a resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders.

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) web site (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

Free annual reports for companies mentioned in the news are available through the Free Annual Reports Service (http://investrend.ar.wilink.com/?level=279).

Powered by EIN Presswire